Student.com, a marketplace for student accommodation, has raised $60 million in investment led by VY Capital, with participation from Horizons Ventures, Expa, Spotify founders Daniel Ek and Martin Lorentzon, and Hugo Barra of Xiaomi. “The student housing market is arguably one of the single biggest industries not yet digitised,” said co-founder Shakil Khan. “WithStudent.com, we’re not only enabling international students the world over to quickly and easily find housing abroad; we’re also giving landlords a digital and global infrastructure to reach millions of students.”
Latch, the creator of a smart lock for the enterprise, has emerged from stealth with a $10.5 million Series A round of funding led by Lux Capital. Latch has now raised a total of $16 million in funding. Primary Venture Partners, Corigin Venture Partners, Camber Creek, Expansion Ventures, PCH, and Wan Li Zhu of Fairhaven Capital also participated in the funding. “We’ve spent the last two years designing and building a beautiful and nearly universal access experience and can’t wait to publicly deploy our product,” said Luke Schoenfelder, Co-Founder and CEO of Latch. “We’re particularly excited that our funding has come not only from great venture capitalists, but from major enterprise customers that stand to save millions of dollars by eliminating the problems they face in managing their tenants, guests, and service providers.”
Yumanity Therapeutics, which aiming to transform drug discovery for diseases caused by protein misfolding, has raised a $45 million Series A financing round. Fidelity Management & Research Company led the round, with participation from Redmile Group, Alexandria Venture Investments, Biogen, Sanofi-Genzyme BioVentures and Dolby Family Ventures. “We are delighted to have the support of such an accomplished group of investors,” said Tony Coles, M.D., chairman and chief executive officer of Yumanity Therapeutics. “This financing is a testament to the work done over the last year building and validating the discovery platforms developed in the laboratory of Dr. Susan Lindquist and to the quality and capability of the company’s scientific team. These proceeds will allow us to devote the resources necessary for our research efforts as we work to discover new drugs for these devastating illnesses. We are strongly positioned to continue executing on the science with the goal of helping the millions of people suffering from neurodegenerative diseases.”